Exosens Shares Drop 2.74% at Midday, RSI Indicates Oversold Condition
The share price of French defense optronics specialist Exosens has fallen by 2.74% to 40.80 euros at midday on Monday, December 1, 2025. This decline occurs in an unfavorable environment, with the CAC 40 itself down by 0.74%, but it accentuates the correction that has been underway for several sessions in the defense sector stock.
Market Performance and Technical Indicators
Since the opening, the stock has fluctuated between 40.70 and 41.85 euros, with very limited trading volumes, representing only 0.05% of the capital traded. Over a week, the decline reaches 3.55%, marking a phase of technical consolidation after an exceptional run since January. Over a year, the performance remains spectacular with an increase of 124.2%, significantly outperforming the CAC 40's 11.44% over the same period. Over three months, the stock still shows an increase of 3.82%, indicating a generally positive momentum despite recent turbulence. Today's decline is part of a delicate technical context. The price is now significantly below its 50-day moving average, set at 45.35 euros, but remains above the 200-day MA at 39.57 euros, which constitutes a long-term support. The RSI indicator is at 27, signaling a marked oversold condition that could favor a technical rebound in the short term. The current level of 40.80 euros is approaching the support threshold identified at 41 euros, while resistance is higher at 49.60 euros.
Financial Performance and Market Analysis
At the end of October, Exosens had posted a nine-month revenue increase of 23.2% to 327.8 million euros, driven by favorable dynamics in defense markets. In October, Deutsche Bank initiated coverage of the stock with a 'hold' recommendation and a target price of 45 euros, considering the valuation correct after a surge of more than 120% since the beginning of the year. The Chaikin Money Flow is at -0.25, confirming selling pressures in the short term, while the MACD histogram remains negative at -0.41, with the MACD line at -1.59 and the signal line at -1.19, indicating a persistent bearish momentum. The one-month volatility is at 10.24%, a relatively contained level for a stock of this size, while a beta of 0.14 illustrates low sensitivity to market movements.
Current Valuation and Outlook
The current valuation of Exosens, around 40.80 euros, positions the stock in a zone of technical focus, between a close psychological support at 41 euros and a 200-day moving average at 39.57 euros. The RSI in the oversold zone suggests potential for a rebound if trading volumes were to increase. The company maintains solid prospects for 2025, with confirmed growth targets, supported by increases in European military budgets and investments announced to expand production capacities. However, the ongoing technical correction also reflects a certain caution among investors after the strong appreciation of the stock since its IPO in June 2024.
